CAMP4 Therapeutics Prices $30M Underwritten Offering Of 5M Shares At $6.00 Each

CAMP4 Therapeutics Corporation ("CAMP4" or the "Company") (NASDAQ:CAMP), a clinical-stage biopharmaceutical company developing a pipeline of regulatory RNA-targeting therapeutics designed to upregulate gene expression with the goal of restoring healthy protein levels to treat a broad range of genetic diseases, today announced the pricing of its underwritten offering of 5,000,000 shares of its common stock at a price of $6.00 per share. The gross proceeds to the Company from this offering are expected to be $30.0 million, before deducting underwriting discounts and commissions and other offering expenses.

The offering is expected to close on or about December 19, 2025, subject to satisfaction of customary closing conditions. All of the securities to be sold in the offering are being offered by the Company.

CAMP4 currently anticipates using the net proceeds from the offering, together with its existing cash, cash equivalents and marketable securities, primarily to support continued development activities for its product candidates, as well as general corporate purposes.